NCT06707987View on ClinicalTrials.gov

Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)

CompletedOBSERVATIONAL

Enrollment

23,250

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

February 1, 2025

Conditions

Acute Ischemic Stroke

Interventions

DRUG

Non-immunogenic staphylokinase

Drug: non-immunogenic staphylokinase 10 mg as a single intravenous bolus Other Names: Fortelyzin®

Trial Locations (1)

117513

Federal Brain and Neurotechnology Center, Moscow

All Listed Sponsors

collaborator

Federal Center of Cerebrovascular Pathology and Stroke, Russian Federation Ministry of Health

OTHER

lead

Supergene, LLC

INDUSTRY

NCT06707987 - Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry) | Biotech Hunter | Biotech Hunter